Director of global health sees cause for optimism on climate change

By Ina Fried

Images of shrinking glaciers and stranded polar bears give powerful evidence of the need for people to work together on the common problem of protecting the planet. Adding art and the voices of community leaders to the data scientists are compiling may help convince decision makers to take action to deal with climate change, said Jonathan Samet, director of the USC Institute for Global Health.

Samet spoke on challenges and opportunities in arts and health care and the need for stewardship of the planet at an Earth Day Forum on April 22 at Los Angeles City Hall. … Read More »

May 16th, 2013|Announcements|

CHLA names Levitt inaugural director of Developmental Neurogenetics

By Ellin Kavanagh

Pat Levitt, USC Provost Professor of Neuroscience, Pharmacy, Psychiatry, Pediatrics and Psychology, has been named inaugural director of the Developmental Neurogenetics Program of the newly created Institute for the Developing Mind within The Saban Research Institute of Children’s Hospital Los Angeles.

The Institute for the Developing Mind, envisioned to become an internationally recognized center for innovative research, diagnosis and treatment of neurodevelopmental and behavioral disorders, will provide comprehensive, interdisciplinary research and clinical services at CHLA and the Keck School of Medicine of USC. … Read More »

May 16th, 2013|Announcements|

HSC Newsmakers

… Read More »

May 16th, 2013|Announcements|

Psychiatry resident wins two key awards

By Josh Grossberg

Beating out hundreds of entrants, a third-year psychiatry resident at the Keck School of Medicine of USC has recently been named the winner of two separate prestigious awards.

Sean Sassano-Higgins was one of only 13 people in the country chosen for a GAP Fellowship, awarded by the Group for the Advancement of Psychiatry. … Read More »

May 16th, 2013|Announcements|

Study shows dual targeting of HER2 and HR-positive metastatic breast cancer improves survival rates

By USC Health Sciences Public Relations and Marketing

A new study from the USC Norris Comprehensive Cancer Center shows targeting both hormone receptors (HRs) and human epidermal growth factor receptor 2 (HER2) in first-line treatment of metastatic breast cancer (MBC) patients significantly increased overall survival times.

A team of researchers led by Debu Tripathy, professor of medicine at the Keck School of Medicine of USC, looked at data provided by RegistHER, a prospective, observational study of 1,023 newly diagnosed HER2-positive metastatic breast cancer patients. They found that hormonal therapy given with the anti-HER2 antibody trastuzumab (Herceptin) and chemotherapy is associated with improved survival and progression-free survival outcomes, compared to no hormonal therapy. … Read More »

May 16th, 2013|Announcements|